GlassScriptPhysician profile
Brian M Smith
NPI 1154395697
$7,441.09
in general payments reported to CMS, 2019-2025
33 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.78 · 2020: $47.61 · 2021: $54.78 · 2022: $177 · 2023: $2,390 · 2024: $2,481 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,087 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,087.03 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.78 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $590.07 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $526.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $518.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.98 | 2022-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $487.33 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $457.56 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $422.70 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $408.57 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $237.00 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $230.53 | 2023-2025 | |
| Exact Sciences Corporation | $225.43 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $216.33 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $146.13 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $138.54 | 2023-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $138.23 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $69.75 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.79 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $50.36 | 2024-2025 | Voquezna |
| Lundbeck LLC | $44.98 | 2023-2025 | Rexulti |
| Ardelyx, INC. | $44.61 | 2025 | Ibsrela |
| Medtronic, INC. | $40.57 | 2023-2024 | Minimed 780g, Aquamantys(Tm) |
| Idorsia Pharmaceuticals US INC | $37.93 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $24.80 | 2022 | |
| Boston Scientific Corporation | $23.12 | 2023 | Watchman Flx |
| Avanos Medical | $20.40 | 2024 | On-Q* Pump and Accessories |
| Xeris Pharmaceuticals, INC. | $20.39 | 2025 | Keveyis |
| Janssen Pharmaceuticals, INC | $15.35 | 2024 | Spravato |
| Kowa Pharmaceuticals America, INC. | $14.34 | 2024 | Zoryve |
| Neurelis, INC. | $14.14 | 2024 | Valtoco |
| Braintree Laboratories, INC. | $13.85 | 2019 | |
| Sanofi Pasteur INC. | $13.80 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.